Physician profile
Arbetta Kambe
NPI 1437267499
$2,670.04
in general payments reported to CMS, 2019-2025
28 companies · $475 in 2025
The $475 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $339 · 2021: $492 · 2022: $264 · 2023: $230 · 2024: $558 · 2025: $475.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,264.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,263.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $529.94 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $318.21 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $211.77 | 2019-2025 | Gardasil 9, Capvaxive, M-M-R II |
| Novo Nordisk INC | $208.20 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $196.11 | 2019-2025 | Mounjaro, Zepbound |
| Abbvie INC. | $144.44 | 2021-2025 | |
| Abbott Laboratories | $139.69 | 2022-2024 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.54 | 2020-2024 | Jardiance, Tradjenta |
| Glaxosmithkline, LLC. | $95.15 | 2020-2025 | Trelegy Ellipta |
| Janssen Pharmaceuticals, INC | $85.96 | 2019-2022 | |
| Shield Therapeutics INC | $81.59 | 2024-2025 | |
| Sanofi Pasteur INC. | $66.21 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $62.60 | 2020-2021 | |
| Exact Sciences Corporation | $59.50 | 2023-2024 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $55.92 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $43.03 | 2021-2023 | |
| Eisai INC. | $39.62 | 2021 | |
| Seqirus USA INC | $31.31 | 2023-2024 | Flucelvax Quadrivalent, Fluad Quadrivalent, Flucelvax |
| Cequr Corporation | $31.11 | 2025 | Cequr Simplicity |
| Dynavax Technologies Corporation | $26.36 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $25.33 | 2025 | Caplyta |
| Shire North American Group INC | $18.89 | 2019 | |
| Medtronic, INC. | $18.06 | 2025 | Intellis Adaptivestim |
| Mylan Pharmaceuticals INC. | $17.09 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.07 | 2023 | Quviviq |
| Otsuka America Pharmaceutical, INC. | $14.41 | 2024 | Rexulti, Abilify Maintena |
| Xeris Pharmaceuticals, INC. | $13.97 | 2021 | |
| Bausch Health US, LLC | $13.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arbetta Kambe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.